AACHEN, Germany, June 2, 2016 /PRNewswire/ --
Agreement includes exclusive rights to Zurampic™ and the fixed-dose combination of lesinurad and allopurinol
Agreement enriches Grünenthal portfolio in the area of inflammatory and pain-related diseases with high unmet...